HAE: Haemonetics Corp.
About
Haemonetics Corp. engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, and Hospital. The Plasma segment offers automated plasma collection and donor management software systems. The Blood Center segment provides solutions for donor collection centers' ability to acquire blood, filter blood, and separate blood components. The Hospital segment includes hemostasis management, cell salvage, and transfusion management services that help decision makers in hospitals optimize blood acquisition, storage, and usage in critical settings. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Boston, MA.
Current Value
$84.751 Year Return
Current Value
$84.751 Year Return
Key Details
Market Cap
$4.26B
P/E Ratio
35.23
1Y Stock Return
2.89%
1Y Revenue Growth
9.84%
Dividend Yield
0.00%
Price to Book
4.9
Strategies that include HAE
Stock's related to HAE
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| KAR | 51.09% | $2.09B | +31.90% | 0.00% |
| HGV | 46.82% | $4.02B | +16.70% | 0.00% |
| VAC | 45.37% | $3.13B | +16.15% | 3.39% |
| CLDT | 45.25% | $425.53M | -12.03% | 3.24% |
| WWW | 44.69% | $1.79B | +171.57% | 1.80% |
| ALNT | 43.74% | $419.62M | -4.92% | 0.36% |
| RAMP | 43.36% | $1.86B | -16.17% | 0.00% |
| BROS | 42.37% | $5.67B | +74.77% | 0.00% |
| FARO | 41.35% | $486.17M | +40.51% | 0.00% |
| GOLF | 41.29% | $4.21B | +20.68% | 1.22% |
| DLX | 39.82% | $1.01B | +24.44% | 5.30% |
| GH | 39.64% | $3.79B | +33.86% | 0.00% |
| ALTG | 38.49% | $236.78M | -29.08% | 3.22% |
| TPVG | 38.46% | $272.08M | - | 18.82% |
| TNL | 38.35% | $3.60B | +42.43% | 3.72% |
| IONQ | 38.20% | $6.04B | +126.93% | 0.00% |
| DLB | 38.05% | $6.76B | -16.58% | 1.69% |
| EPAM | 37.88% | $12.91B | -11.78% | 0.00% |
| IIPR | 37.54% | $3.01B | +33.85% | 7.00% |
| NXRT | 37.16% | $1.17B | +52.21% | 4.03% |
ETF's related to HAE
News
Yahoo
A few of its recent strategic acquisitions that are likely to drive future growth for TMO include the $3.1-billion acquisition of Olink Holdings.
Yahoo
BellRing Brands (BRBR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Yahoo
Zimmer Biomet gets CE Mark Certification for Persona Revision Knee System, followed by the successful introduction in the United States and other markets.
Yahoo
Illumina's new TSO 500 v2 assay aims to enable CGP of tumors, bolstering its TruSight Oncology portfolio.
Yahoo
Investors remain optimistic about Boston Scientific due to its geographical expansions and impressive acquisitions.
Yahoo
Boston Scientific announces favorable OPTION trial results for its WATCHMAN FLX LAAC device. In terms of stroke risk reduction, WATCHMAN FLX is found to be superior to OAC therapy.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.